1-(4-bromobutyl)-4-methylbenzene | 99857-43-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-bromobutyl)-4-methylbenzene
• CAS: 99857-43-9
• 化学式: C₁₁H₁₅Br
• 分子量: 227.144
• InChiKey: FCYSNQACNGYXEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(4-bromobutyl)-4-methylbenzene 在 potassium cyanide 、 乙醇 作用下， 生成 5-(4-甲基苯基)缬草酸
  参考文献：
  名称：

  Huisgen; Vossius, Monatshefte fur Chemie, 1957, vol. 88, p. 517,527

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 4-(p-tolyl)butanoate 在 磷化氢 、 lithium aluminium tetrahydride 、 乙醚 、 硫酸 、 氢溴酸 作用下， 生成 1-(4-bromobutyl)-4-methylbenzene
  参考文献：
  名称：

  Huisgen; Vossius, Monatshefte fur Chemie, 1957, vol. 88, p. 517,527

  摘要：

  DOI：

文献信息

• Iridium‐Catalyzed Regio‐ and Enantioselective Borylation of Unbiased Methylene C(sp ³ )−H Bonds at the Position β to a Nitrogen Center
  作者：Rongrong Du、Luhua Liu、Senmiao Xu

  DOI：10.1002/anie.202016009

  日期：2021.3.8

  pyrazole‐directed iridium‐catalyzed enantioselective borylation of unbiased methylene C−H bonds at the position β to a nitrogen center. The combination of a chiral bidentate boryl ligand, iridium precursor, and pyrazole directing group was responsible for the high regio‐ and enantioselectivity observed. The method tolerated a vast array of functional groups to afford the corresponding C(sp3)−H functionalization

  本文报道的是吡唑导向的铱催化的对位氮原子中心的无偏亚甲基CH键的对映选择性硼化。手性双齿硼基配体，铱前体和吡唑导向基团的结合是观察到的高区域选择性和对映选择性的原因。该方法耐受大量官能团，以提供具有良好至优异对映选择性的相应C（sp 3）-H功能化产物。
• Remote Migratory Cross-Electrophile Coupling and Olefin Hydroarylation Reactions Enabled by in Situ Generation of NiH
  作者：Fenglin Chen、Ke Chen、Yao Zhang、Yuli He、Yi-Ming Wang、Shaolin Zhu

  DOI：10.1021/jacs.7b08064

  日期：2017.10.4

  ligand-controlled nickel migration/arylation. This general protocol allows the use of abundant and bench-stable alkyl bromides and aryl bromides for the synthesis of a wide range of structurally diverse 1,1-diarylalkanes in excellent yields and high regioselectivities under mild conditions. We also demonstrated that alkyl bromide could be replaced by the proposed olefin intermediate while using n-propyl bromide/Mn0

  通过配体控制的镍迁移/芳构化，已经开发出一种用于远程还原性交亲电试剂偶联的高效策略。该通用方案允许使用大量稳定的烷基溴化物和芳基溴化物，在温和条件下以优异的收率和高区域选择性合成各种结构多样的1,1-二芳基烷烃。我们还证明，在使用正丙基溴/ Mn 0作为潜在的氢化物源的同时，烷基溴可以被提议的烯烃中间体替代。
• Substrate and Catalyst Effects in the Enantioselective Copper-Catalysed C-H Insertion Reactions of α-Diazo-β-oxo Sulfones
  作者：Amy E. Shiely、Leslie-Ann Clarke、Christopher J. Flynn、Aoife M. Buckley、Alan Ford、Simon E. Lawrence、Anita R. Maguire

  DOI：10.1002/ejoc.201800077

  日期：2018.5.24

  Irish Research Council (Project Numbers GOIPG/2013/1064 and GOIPG/2013/225); Science Foundation Ireland (Grant Number 02/PICA/B802/EC07)

  爱尔兰研究委员会（项目编号 GOIPG/2013/1064 和 GOIPG/2013/225）；爱尔兰科学基金会（授权号 02/PICA/B802/EC07）
• Preparation of Sterically Protected 3,4-Bis[(2,4,6-tri-<i>t</i>-butylphenyl)phosphinidene]-1,2-bis[4-(4-vinylphenyl)butyl]cyclobutene and Its Polymers
  作者：Naoki Yamada、Kozo Toyota、Masaaki Yoshifuji

  DOI：10.1246/cl.2001.248

  日期：2001.3

  Two new sterically protected 3,4-diphosphinidenecyclobutenes, i.e., 1,2-bis[4-(4-methylphenyl)butyl]-3,4-bis[(2,4,6-tri-t-butylphenyl)phosphinidene]cyclobutene, and 3,4-bis[(2,4,6-tri-t-butylphenyl)phosphinidene]-1,2-bis[4-(4-vinylphenyl)butyl]cyclobutene, were prepared. Copolymerization of the latter with styrene was studied. Treatment of [6-(4-vinylphenyl)hex-1-ynyl](2,4,6-tri-t-butylphenyl)phosphine with butyllithium and 1,2-dibromoethane afforded a polymer of the latter cyclobutene.

  两种具有立体保护的3,4-二膦烯环丁烯新化合物被制备，即1,2-二[4-(4-甲基苯基)丁基]-3,4-二[(2,4,6-三叔丁基苯基)膦烯]环丁烯和3,4-二[(2,4,6-三叔丁基苯基)膦烯]-1,2-二[4-(4-乙烯基苯基)丁基]环丁烯。后者与苯乙烯的共聚合进行了研究。用丁基锂和1,2-二溴乙烷处理[6-(4-乙烯基苯基)己-1-炔基](2,4,6-三叔丁基苯基)膦，得到后者的环丁烯聚合物。
• Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
  申请人：Roche Diagnostics GmbH

  公开号：US06472396B1

  公开（公告）日：2002-10-29

  Compounds of formula I, useful as matrix metalloprotease inhibitors, wherein X, Y and Z are each oxygen; R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen; R2 and R3 are each hydrogen; and R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C1-C6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl and cyano.

  化合物I的式子，可用作基质金属蛋白酶抑制剂，其中X、Y和Z均为氧；R1选自（a）正辛基，（b）正癸基，（c）联苯基和（d）（4-苯氧基）苯基，其中对于基团（c）-（d）的末端单环可以是未取代的或取代的，所取代基团选自—NH2，—NO2，—SO2NH2，—SO2CH3，乙酰基，羟基，甲氧基，乙氧基，氰基和卤素；R2和R3均为氢；R4和R5与它们所连接的氮原子一起形成哌嗪基或哌啶基环，其中哌嗪基环在4位上被选自以下基团的取代基所取代：（a）具有0、1或2个氮原子和单环中其余原子为碳的6-成员芳香单环和（b）羟基-C1-C6烷基，其中单环未取代或被选自卤素，—NH2，—NO2，—SO2NH2，—SO2CH3，乙酰基和氰基的取代基所取代。